Director of National Intelligence Tulsi Gabbard has released declassified records detailing U.S. funding for biological laboratories overseas, reviving a politically sensitive debate over American-backed pathogen research, transparency and the line between public health programs and national security risks.
The records, released by the Office of the Director of National Intelligence, describe longstanding U.S. government support for more than 120 biological laboratories across more than 30 countries. The documents include references to facilities in Ukraine, where some laboratories reportedly stored or studied dangerous pathogens and received U.S.-funded training, upgrades and biocontainment support.
Gabbard said the release validates concerns that were previously dismissed as misinformation. Her comments refer to the controversy that followed Russia’s 2022 invasion of Ukraine, when claims about U.S.-funded biological laboratories became a major flashpoint. Critics accused Gabbard and others of amplifying Russian narratives, while supporters argued that legitimate questions about U.S. funding, oversight and biosecurity risks were being treated as disinformation.
The newly declassified materials are likely to intensify that debate rather than settle it.
TRENDING TODAY
According to ODNI materials, U.S. funding supported a network of laboratories that handled or stored dangerous pathogens, including some collections dating back to the Soviet era. Some records describe Ukrainian facilities that received U.S.-backed upgrades and training under programs intended to improve biological safety, secure dangerous materials and reduce proliferation risks.
The documents reportedly reference pathogens such as anthrax, plague, tuberculosis, Ebola, Marburg, MERS and SARS. The presence of such pathogens does not by itself prove a biological weapons program. Public health, veterinary and research laboratories may store or study dangerous pathogens for disease surveillance, diagnostics, vaccine research or threat-reduction purposes.
That distinction is central to the controversy.
Gabbard and other critics argue that the public was not given a full or transparent picture of the scale of U.S.-supported biological research overseas. They say Americans deserved clearer information about where taxpayer money was going, what pathogens were involved, which contractors participated and what safeguards were in place.
Supporters of the programs argue that many of the facilities were part of long-running threat-reduction efforts that began after the collapse of the Soviet Union. The goal, they say, was to secure dangerous pathogens, prevent biological proliferation and strengthen public health systems in countries where Soviet-era disease collections and laboratory networks remained.
Ukraine’s Ministry of Health has denied that its laboratories are designed for biological weapons research, saying the facilities operate legally as diagnostic, scientific or reference laboratories in the public health, veterinary or research sectors. Ukrainian officials have argued that Russian claims about “biolabs” have been used for propaganda purposes during the war.
The release therefore creates a careful but important distinction: the records appear to confirm U.S. support for biological laboratories and pathogen-security programs overseas, including in Ukraine. They do not, based on the information released so far, prove that the United States or Ukraine operated a biological weapons program.
Still, the documents raise real policy questions. One concern is whether programs involving dangerous pathogens received enough public oversight. Another is whether U.S.-funded overseas laboratories have consistent safety standards, especially in countries facing war, corruption risks or weak institutions. A third is how governments should communicate about sensitive biosecurity work without creating secrecy that fuels public mistrust.
The issue also overlaps with a wider debate over gain-of-function research and pandemic preparedness. Since COVID-19, lawmakers and public health experts have argued over whether research involving dangerous pathogens should face stricter rules, especially when funded abroad. The Trump administration has moved to restrict certain risky research overseas, while critics of those restrictions warn that poorly designed limits could weaken disease surveillance.
Gabbard’s release is likely to be welcomed by lawmakers and activists who have demanded more transparency around U.S.-funded biological research. It is also likely to be criticized by those who worry that the documents may be used to blur the line between legitimate public health laboratories and unproven claims about weapons programs.
That tension will shape the political response. Republicans are likely to frame the records as evidence that earlier dismissals of “biolab” concerns were too broad. Democrats and public health officials may respond that U.S.-supported labs were known threat-reduction programs and that the new release does not validate Russian claims about biological weapons.
For the public, the challenge is separating three different questions: whether U.S. funding existed, whether dangerous pathogens were handled, and whether any illegal weapons work occurred. The first two may be supported by the records. The third remains a far stronger claim and has not been proven by the materials released so far.
The broader lesson may be about trust. When governments label sensitive questions as misinformation without clearly explaining the underlying facts, suspicion can grow. But when political figures present complex public health programs as something more sinister than the evidence supports, confusion also deepens.
Gabbard’s declassification has reopened the conversation. Now the next question is whether it leads to serious oversight or another partisan fight over pandemic-era mistrust, Ukraine policy and the role of U.S. funding in biological research abroad.
Why It Matters
The release matters because it touches several high-stakes issues at once: government transparency, U.S. funding overseas, biosecurity, Ukraine, Russia’s information war and public trust after COVID-19.
The documents may support calls for more oversight of U.S.-funded pathogen research abroad. But they also require careful interpretation, because confirming the existence of U.S.-supported biological laboratories is not the same as proving a biological weapons program.
What Comes Next
Lawmakers may seek hearings or additional records about which agencies funded the laboratories, what contractors were involved and what safety rules governed the programs.
Public health officials and Ukraine’s government are also likely to continue pushing back against claims that the laboratories were used for weapons development. The debate will likely continue as more documents are reviewed and as the Trump administration tightens rules around overseas biological research funding.
Gabbard released declassified intelligence materials on U.S.-funded biological laboratories overseas, saying the records raise new questions about transparency and oversight.
🚨Was Tulsi Gabbard pushed out because of the biolab files?
Tulsi Gabbard is now releasing declassified intelligence claiming past U.S. government funding for more than 120 biological laboratories in over 30 countries, including Ukraine.
Officially, this is part of President… pic.twitter.com/F58HbjEwIF
— Skywatch Signal (@UAPWatchers) June 13, 2026
